BNP Paribas Financial Markets’s Charles River Laboratories CRL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$69.1M Buy
304,725
+52,536
+21% +$9.36M 0.02% 605
2026
Q1
$43.5M Buy
252,189
+89,449
+55% +$16.6M 0.02% 748
2025
Q4
$32.5M Buy
162,740
+52,861
+48% +$9.59M 0.01% 904
2025
Q3
$17.2M Buy
109,879
+20,224
+23% +$3.21M 0.01% 1198
2025
Q2
$13.6M Sell
89,655
-4,978
-5% -$664K 0.01% 1241
2025
Q1
$14.2M Buy
94,633
+4,550
+5% +$763K 0.01% 1207
2024
Q4
$16.6M Buy
90,083
+10,912
+14% +$2.1M 0.01% 1099
2024
Q3
$15.6M Sell
79,171
-48,659
-38% -$10.1M 0.01% 976
2024
Q2
$26.4M Buy
127,830
+60,682
+90% +$13.7M 0.02% 657
2024
Q1
$18.2M Buy
67,148
+20,941
+45% +$5M 0.02% 823
2023
Q4
$10.9M Sell
46,207
-1,437
-3% -$283K 0.01% 987
2023
Q3
$9.34M Buy
47,644
+7,542
+19% +$1.55M 0.01% 928
2023
Q2
$8.43M Sell
40,102
-39,236
-49% -$7.81M 0.01% 980
2023
Q1
$16M Buy
79,338
+16,840
+27% +$3.82M 0.02% 684
2022
Q4
$13.6M Buy
62,498
+13,436
+27% +$2.93M 0.02% 823
2022
Q3
$9.66M Sell
49,062
-21,762
-31% -$4.7M 0.02% 994
2022
Q2
$15.2M Buy
70,824
+53,655
+313% +$13.1M 0.02% 703
2022
Q1
$4.88M Sell
17,169
-18,088
-51% -$5.58M 0.01% 1313
2021
Q4
$13.3M Sell
35,257
-16,869
-32% -$6.55M 0.02% 830
2021
Q3
$21.5M Buy
52,126
+512
+1% +$213K 0.03% 573
2021
Q2
$19.1M Buy
51,614
+28,542
+124% +$9.53M 0.03% 665
2021
Q1
$6.69M Buy
23,072
+14,384
+166% +$4M 0.01% 1009
2020
Q4
$2.17M Sell
8,688
-7,144
-45% -$1.7M ﹤0.01% 1592
2020
Q3
$3.59M Buy
15,832
+8,290
+110% +$1.72M 0.01% 1239
2020
Q2
$1.31M Sell
7,542
-19,091
-72% -$3.05M ﹤0.01% 1671
2020
Q1
$3.36M Sell
26,633
-52,493
-66% -$7.87M 0.01% 1197
2019
Q4
$12.1M Sell
79,126
-5,449
-6% -$754K 0.02% 728
2019
Q3
$11.2M Sell
84,575
-49,074
-37% -$6.58M 0.02% 725
2019
Q2
$19M Buy
133,649
+110,985
+490% +$15.1M 0.04% 471
2019
Q1
$3.29M Buy
22,664
+15,927
+236% +$2.09M 0.01% 1170
2018
Q4
$762K Sell
6,737
-29,670
-81% -$3.71M ﹤0.01% 1685
2018
Q3
$4.9M Buy
36,407
+23,484
+182% +$2.9M 0.01% 1148
2018
Q2
$1.45M Sell
12,923
-20,807
-62% -$2.25M ﹤0.01% 1619
2018
Q1
$3.6M Buy
33,730
+17,846
+112% +$1.92M 0.01% 1141
2017
Q4
$1.74M Sell
15,884
-6,119
-28% -$666K ﹤0.01% 1570
2017
Q3
$2.38M Sell
22,003
-3,315
-13% -$341K 0.01% 1059
2017
Q2
$2.56M Buy
25,318
+5,743
+29% +$529K 0.01% 1056
2017
Q1
$1.76M Sell
19,575
-982
-5% -$83.4K ﹤0.01% 1117
2016
Q4
$1.57M Sell
20,557
-150,020
-88% -$11.4M 0.01% 1079
2016
Q3
$14.2M Buy
170,577
+144,702
+559% +$12.1M 0.06% 227
2016
Q2
$2.13M Sell
25,875
-3,636
-12% -$299K 0.01% 841
2016
Q1
$2.24M Buy
29,511
+19,572
+197% +$1.45M 0.01% 784
2015
Q4
$799K Sell
9,939
-1,057
-10% -$76.2K ﹤0.01% 979
2015
Q3
$698K Buy
10,996
+1,133
+11% +$81.4K ﹤0.01% 1199
2015
Q2
$694K Buy
9,863
+8,147
+475% +$603K ﹤0.01% 1234
2015
Q1
$136K Buy
1,716
+733
+75% +$54.1K ﹤0.01% 1661
2014
Q4
$62.6K Sell
983
-4,707
-83% -$295K ﹤0.01% 1637
2014
Q3
$340K Sell
5,690
-888
-13% -$50.8K ﹤0.01% 1666
2014
Q2
$352K Sell
6,578
-1,867
-22% -$102K ﹤0.01% 1627
2014
Q1
$454K Buy
8,445
+7,479
+774% +$436K ﹤0.01% 1480
2013
Q4
$51.2K Buy
+966
New +$48.5K ﹤0.01% 1907

Other funds holding CRL

BNP Paribas Financial Markets's CRL Position: Q2 2026 in Review

BNP Paribas Financial Markets increased its Charles River Laboratories (CRL) stake by 21% in Q2 2026, buying an estimated $9.36M and bringing the position to 304,725 shares worth $69.1M. The position accounts for 0.02% of the portfolio, ranked #605.

BNP Paribas Financial Markets first reported a position in CRL in Q4 2013 and has held it in 51 quarters since. 568 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • BNP Paribas Financial Markets held 304,725 shares of Charles River Laboratories worth $69.1M as of Q2 2026.
  • BNP Paribas Financial Markets bought 52,536 Charles River Laboratories shares in Q2 2026, an estimated $9.36M.
  • Charles River Laboratories made up 0.02% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #605 holding.
  • BNP Paribas Financial Markets first reported a position in Charles River Laboratories in Q4 2013 and has held it in 51 quarters since.
  • 568 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.